Antibody-directed targeting of the vasculature of solid tumors

Philip E. Thorpe, Francis J. Burrows

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

An attractive strategy for the therapy of carcinomas and other solid tumors would be to target cytotoxic agents or host immune effectors to the endothelial cells of the tumor vasculature rather than to the tumor cells themselves. The key advantage of this approach is that the endothelial cells are freely accessible through the blood whereas the tumor cells are, for the most part, inaccessible. Also, endothelial cells are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. In this chapter, we review progress in this "vascular targeting" approach, from the validation of the concept in a mouse model to the characterization of the TEC-11 antibody against endoglin, an endothelial cell proliferation marker that is upregulated on endothelial cells in miscellaneous human solid tumors. In addition, we review other tumor endothelial cell markers that are candidates for vascular targeting in man.

Original languageEnglish (US)
Pages (from-to)237-251
Number of pages15
JournalBreast Cancer Research and Treatment
Volume36
Issue number2
DOIs
StatePublished - Jan 1995

Fingerprint

Endothelial Cells
Antibodies
Neoplasms
Blood Vessels
Cytotoxins
Cell Proliferation
Carcinoma
Therapeutics

Keywords

  • endothelial cells
  • monoclonal antibodies
  • solid tumors
  • TEC-11 antibody
  • therapy
  • vascular targeting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antibody-directed targeting of the vasculature of solid tumors. / Thorpe, Philip E.; Burrows, Francis J.

In: Breast Cancer Research and Treatment, Vol. 36, No. 2, 01.1995, p. 237-251.

Research output: Contribution to journalArticle

Thorpe, Philip E. ; Burrows, Francis J. / Antibody-directed targeting of the vasculature of solid tumors. In: Breast Cancer Research and Treatment. 1995 ; Vol. 36, No. 2. pp. 237-251.
@article{bab211b4c192457b82db57865dc57854,
title = "Antibody-directed targeting of the vasculature of solid tumors",
abstract = "An attractive strategy for the therapy of carcinomas and other solid tumors would be to target cytotoxic agents or host immune effectors to the endothelial cells of the tumor vasculature rather than to the tumor cells themselves. The key advantage of this approach is that the endothelial cells are freely accessible through the blood whereas the tumor cells are, for the most part, inaccessible. Also, endothelial cells are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. In this chapter, we review progress in this {"}vascular targeting{"} approach, from the validation of the concept in a mouse model to the characterization of the TEC-11 antibody against endoglin, an endothelial cell proliferation marker that is upregulated on endothelial cells in miscellaneous human solid tumors. In addition, we review other tumor endothelial cell markers that are candidates for vascular targeting in man.",
keywords = "endothelial cells, monoclonal antibodies, solid tumors, TEC-11 antibody, therapy, vascular targeting",
author = "Thorpe, {Philip E.} and Burrows, {Francis J.}",
year = "1995",
month = "1",
doi = "10.1007/BF00666044",
language = "English (US)",
volume = "36",
pages = "237--251",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Antibody-directed targeting of the vasculature of solid tumors

AU - Thorpe, Philip E.

AU - Burrows, Francis J.

PY - 1995/1

Y1 - 1995/1

N2 - An attractive strategy for the therapy of carcinomas and other solid tumors would be to target cytotoxic agents or host immune effectors to the endothelial cells of the tumor vasculature rather than to the tumor cells themselves. The key advantage of this approach is that the endothelial cells are freely accessible through the blood whereas the tumor cells are, for the most part, inaccessible. Also, endothelial cells are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. In this chapter, we review progress in this "vascular targeting" approach, from the validation of the concept in a mouse model to the characterization of the TEC-11 antibody against endoglin, an endothelial cell proliferation marker that is upregulated on endothelial cells in miscellaneous human solid tumors. In addition, we review other tumor endothelial cell markers that are candidates for vascular targeting in man.

AB - An attractive strategy for the therapy of carcinomas and other solid tumors would be to target cytotoxic agents or host immune effectors to the endothelial cells of the tumor vasculature rather than to the tumor cells themselves. The key advantage of this approach is that the endothelial cells are freely accessible through the blood whereas the tumor cells are, for the most part, inaccessible. Also, endothelial cells are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. In this chapter, we review progress in this "vascular targeting" approach, from the validation of the concept in a mouse model to the characterization of the TEC-11 antibody against endoglin, an endothelial cell proliferation marker that is upregulated on endothelial cells in miscellaneous human solid tumors. In addition, we review other tumor endothelial cell markers that are candidates for vascular targeting in man.

KW - endothelial cells

KW - monoclonal antibodies

KW - solid tumors

KW - TEC-11 antibody

KW - therapy

KW - vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0029098530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029098530&partnerID=8YFLogxK

U2 - 10.1007/BF00666044

DO - 10.1007/BF00666044

M3 - Article

C2 - 8534871

AN - SCOPUS:0029098530

VL - 36

SP - 237

EP - 251

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -